StockData
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc. (AVIR) stock

AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$3.96−0.16 (-3.88%)

Close on Nov 17, 2026Market cap $317.61MP/E –Yield –

Atea Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Atea Pharmaceuticals's pe ratio was 13.2× on Jan 31, 2023, against 24.0× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Jan 31, 202313.2×−0.5
2022Dec 30, 202213.7×−16.3
2021Dec 31, 202130.0×–

More Atea Pharmaceuticals figures

See a number that looks wrong?